Please login to the form below

Not currently logged in
Email:
Password:

bone cancer

This page shows the latest bone cancer news and features for those working in and with pharma, biotech and healthcare.

BMS/bluebird bio resubmit FDA application for myeloma CAR-T

BMS/bluebird bio resubmit FDA application for myeloma CAR-T

In addition, 100% of evaluable patients achieved early minimal residual disease-negative status at day 28 post-infusions, which means that there was no detectable cancer cells in their bone marrow.

Latest news

More from news
Approximately 1 fully matching, plus 67 partially matching documents found.

Latest Intelligence

  • Addressing the payer-regulator evidence gap in early-stage cancer Addressing the payer-regulator evidence gap in early-stage cancer

    By Jason Ward. In 2018, more than four million people across Europe were diagnosed with some form of cancer. ... These events may include the return of the cancer or the onset of certain symptoms, such as bone pain from cancer that has spread to the bone.

  • Deal Watch September 2016 Deal Watch September 2016

    Dr Reddy's has expanded its collaboration with Amgen in India adding three approved products: Xgeva for treating bone metastases, Vectibix in colorectal cancer therapy and Prolia for osteoporosis. ... Janssen granted Tracon Pharmaceuticals the rights to

  • Case study: Treatment guidance Case study: Treatment guidance

    Mifamurtide is a treatment for children, adolescents and young adults with a rare type of bone cancer, osteosarcoma.

  • Pharma deals during April 2014 Pharma deals during April 2014

    Jakavi (rare bone marrow disorder); Signifor (Cushing's disease) plus 16 products in 24 pivotal trials. . ... Additional revenues for these two drugs are also promised in other cancer types not to mention their “combo” potential.

  • The distressing impact of rare diseases The distressing impact of rare diseases

    A US patient with Multiple Hereditary Exostosis (that can cause bone cancer) quoted in the report said: “Finding a doctor that can treat me is the most difficult part.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...

Infographics